In this study, we discovered that BRD2 mRNA expression showed better OS in all the ovarian malignancy patients, serous ovarian cancer patients, advanced clinical stage (III and IV), pathological grade (II and III) ovarian cancer patients as well as all patients treated with Platin based chemotherapy, suggesting that BRD2 represent a favorable prognostic marker for patients with ovarian malignancy, specifically in poor differentiation and advanced clinical stage serous ovarian cancer patients. This evidence concerns the gene BRD2 and ovarian carcinoma.